
News|Articles|March 2, 2026
FDA updates in urology: February 2026
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
A recap of the FDA submissions and regulatory decisions in urology from February 2026.
Advertisement
Advertisement
Welcome to Urology Times’® monthly FDA update! February’s regulatory news was characterized by updates in the men’s and women’s health space, in addition to a notable milestone in the development of an investigational agent for urothelial carcinoma. At the end of February, the field also saw 2 FDA submissions for belzutifan-based combinations in kidney cancer based on data presented at the 2026
Related to this article

The approval is supported by data from the phase 3 VOLGA trial.

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.

VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.

The combination of nogapendekin alfa inbakicept plus BCG demonstrated a statistically significant improvement in efficacy vs BCG alone.
Advertisement
Advertisement


